GH and IGF-1 increased
Early pharmacology studies evaluated whether CJC-1295 could produce sustained changes in growth hormone and IGF-1.
Traducción automática para su comodidad. Para decisiones médicas,
confirme los detalles con nuestro equipo bilingüe.
Not FDA-Approved
CJC-1295: evidence, status & safety
CJC-1295 is a long-acting growth hormone-releasing hormone analog studied for its effects on growth hormone and IGF-1. It is not an FDA-approved drug.
Clinical Snapshot
What patients should know first
Early human pharmacology findings can show that a substance affects a biological pathway without establishing that it improves meaningful patient outcomes.
Commonly discussed for
Sleep, lean mass, fat loss, recovery, performance and
anti-aging.
What efficacy data show
Small, short human studies showed prolonged increases in
growth hormone and IGF-1. Those pharmacologic findings do not
by themselves establish durable improvements in body
composition, recovery, function, longevity or other wellness
outcomes.
Approval boundary
A biomarker response is evidence of pharmacologic activity;
it is not proof of a meaningful clinical benefit or FDA
approval.
Safety context
Long-term safety information remains limited. Questions about
endocrine effects, product identity, manufacturing quality
and peptide-related impurities remain separate from whether a
substance can change GH or IGF-1 levels.
Evidence Context
A biological response is not the same as clinical benefit
Understanding this distinction is especially important when a research peptide is marketed with broad claims involving body composition, recovery, performance or longevity.
Pharmacologic activity
A measurable change in a hormone or biomarker can demonstrate activity without proving that patients experience a lasting improvement in health or function.
Proven wellness outcomes
Biomarker changes alone do not establish improved recovery, body composition, performance, longevity or other commonly marketed wellness claims.
Interpretation
Do not confuse a molecule with a verified medication
The name of an active ingredient does not verify the product in a vial. FDA approval, when it exists, applies to a specific product and indication. A compounded version is not FDA-approved, and a research-labeled product is not approved for human use.
Clinical supervision should include diagnosis, contraindication and interaction review, realistic outcome discussion, a valid prescription, traceable sourcing and follow-up. It cannot make an anonymous or counterfeit product safe.
Primary Sources
Verify the evidence
Product claims should be checked against published human research, regulatory information and independent pharmacy verification resources.
Evidence Before Treatment
This guide is educational and does not establish that CJC-1295 is safe, effective or appropriate for human treatment. CJC-1295 is not an FDA-approved drug. Changes in growth hormone or IGF-1 should not be interpreted as proof of improved recovery, performance, body composition, longevity or other clinical outcomes.